Following New York state guidance, MSK has suspended offering the J & J/Janssen vaccine. We continue to offer the Pfizer-BioNTech and Moderna vaccines to our eligible patients. Appointments can be scheduled here. For more on the J & J vaccine, read this.
Scott Millman, MD, PhD
Acute and Chronic Leukemias; Myelodysplastic Syndrome; Myeloproliferative Neoplasms
During my training as a physician-scientist, I benefited greatly from exposure to the exciting discoveries and breakthroughs that emerged in the cancer research field over the past decade. It is my goal to continue these efforts in the laboratory, specifically conducting research on the metabolism of blood cancer cells to develop new and better treatments for our patients. Our ambition is that these new approaches can quickly advance to clinical trials here at MSK.
A diagnosis of leukemia or the start of a new treatment can be a very challenging time for a patient and their family. When in the hospital, I strive to make sure that our treatment team — a dedicated group of doctors, nurses, pharmacists, and support staff — is providing the best care possible. To me, that means not only delivering the highest quality medical treatment, but also removing some of the uncertainty from the process. I aim to review the rationales, logistics, and expectations for our therapies with each patient I meet. My hope is that the more effectively we communicate, the better experience our patients will have.
When in the hospital, I strive to make sure that our treatment team — a dedicated group of doctors, nurses, pharmacists, and support staff — is providing the best care possible.
Awards and Honors
Research Training Award for Fellows, American Society of Hematology
Clinical Scholars Biomedical Research Fellowship, Memorial Sloan Kettering Cancer Center
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Scott Millman discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at firstname.lastname@example.org.